Biogen Inc
(BSP:BIIB34)
R$
169.49
1.36 (0.81%)
Market Cap: 149.37 Bil
Enterprise Value: 178.06 Bil
PE Ratio: 15.80
PB Ratio: 1.56
GF Score: 75/100 Biogen Inc at Leerink CybeRx Series CNS Forum Transcript
Jun 23, 2020 / 04:30PM GMT
Release Date Price:
R$232.82
Marc Harold Goodman
SVB Leerink LLC, Research Division - MD of Neuroscience & Senior Research Analyst
All right. Good afternoon, everybody. Welcome back. We are lucky enough for our next session to have Chris Henderson, who is the Head of Research at a little company called Biogen. And Chris, you've been in this new role now since March, but you have been in this organization for almost 6 years.
Questions & Answers
Marc Harold Goodman
SVB Leerink LLC, Research Division - MD of Neuroscience & Senior Research Analyst
So maybe you could just give us just a sense of behind the scenes at Biogen, talk about the general strategy of R&D there, your research capabilities, the R&D mantra, how maybe you're even different from a few other organizations, just quickly just set the stage?
Christopher Henderson
Biogen Inc. - VP & Head of Neuromuscular & Movement Disorders Research Unit
Yes, I think that's a really good way to start, actually, because I think our main mantra is what separates us
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot